| Delårsrapport januari – september 2022 | Report (pdf) |
| Promore Pharma Delårsrapport januari – juni 2022 | Report (pdf) |
| Promore Pharma — delårsrapport januari-mars 2022 | Report (pdf) |
| Delårsrapport januari – December 2021 | Report (pdf) |
The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.
To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.
To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.